{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Anti-HSV-2 activity", "Attachment assay", "Penetration assay", "Post-infection plaque reduction assay", "Terminalia chebula"]], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": ["IM"], "GeneralNote": [], "PMID": "28196487", "DateCompleted": {"Year": "2017", "Month": "02", "Day": "23"}, "DateRevised": {"Year": "2019", "Month": "12", "Day": "10"}, "Article": {"ArticleDate": [{"Year": "2017", "Month": "02", "Day": "14"}], "Language": ["eng"], "ELocationID": ["110", "10.1186/s12906-017-1620-8"], "Journal": {"ISSN": "1472-6882", "JournalIssue": {"Volume": "17", "Issue": "1", "PubDate": {"Year": "2017", "Month": "Feb", "Day": "14"}}, "Title": "BMC complementary and alternative medicine", "ISOAbbreviation": "BMC Complement Altern Med"}, "ArticleTitle": "Anti-HSV-2 activity of Terminalia chebula Retz extract and its constituents, chebulagic and chebulinic acids.", "Pagination": {"StartPage": "110", "MedlinePgn": "110"}, "Abstract": {"AbstractText": ["Development of new and effective therapeutics for sexually transmitted herpes simplex virus-2 (HSV-2) infection is important from public health perspective. With an aim to identify natural products from medicinal plants, in the present study, the potential of Terminalia chebula Retz was investigated for its activity against HSV-2.", "Fruits of Terminalia chebula Retz were used to prepare 50% ethanolic extract. In addition, chebulagic acid and chebulinic acid both purified from T. chebula were also used. The extract as well as purified compounds were first used to determine their in vitro cytotoxicity on Vero cells by MTT assay. T. chebula extract, chebulagic acid, chebulinic acid along with acyclovir were subsequently assessed for direct anti-viral activity, and their ability to inhibit attachment and penetration of HSV-2 to the Vero cells. In addition, their anti-HSV-2 activity was also determined by in vitro post-infection plaque reduction assay.", "Cytotoxicity assay using Vero cells revealed CC<sub>50</sub>\u2009=\u2009409.71\u2009\u00b1\u200947.70\u00a0\u03bcg/ml for the extract whereas chebulagic acid and chebulinic acid showed more than 95% cell viability up to 200\u00a0\u03bcg/ml. The extract from T. chebula (IC<sub>50</sub>\u2009=\u20090.01\u2009\u00b1\u20090.0002\u00a0\u03bcg/ml), chebulagic (IC<sub>50</sub>\u2009=\u20091.41\u2009\u00b1\u20090.51\u00a0\u03bcg/ml) and chebulinic acids (IC<sub>50</sub>\u2009=\u20090.06\u2009\u00b1\u20090.002\u00a0\u03bcg/ml) showed dose dependent potent in vitro direct anti-viral activity against HSV-2. These also effectively prevented the attachment as well as penetration of the HSV-2 to Vero cells. In comparison, acyclovir showed poor direct anti-viral activity and failed to significantly (p\u2009>\u20090.05) prevent the attachment as well as penetration of HSV-2 to Vero cells when tested upto 50\u00a0\u03bcg/ml. However, in post-infection plaque reduction assay, T. chebula extract, chebulagic and chebulinic acids showed IC<sub>50</sub> values of 50.06\u2009\u00b1\u20096.12, 31.84\u2009\u00b1\u20092.64, and 8.69\u2009\u00b1\u20092.09\u00a0\u03bcg/ml, respectively, which were much lower than acyclovir (71.80\u2009\u00b1\u200919.95\u00a0ng/ml).", "The results presented herein suggest that T. chebula extract, chebulagic and chebulinic acids have higher direct antiviral activity against HSV-2 and efficacy to inhibit virus attachment and penetration to the host cells as compared to acyclovir. However, acyclovir is more potent to inhibit post-infection virus replication. Hence, T. chebula may be a useful candidate for developing alternative therapy for prevention of sexually transmitted HSV-2 infection. \u115f."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Reproductive Cell Biology Laboratory, National Institute of Immunology, Aruna Asaf Ali Marg, New Delhi, 110 067, India."}, {"Identifier": [], "Affiliation": "Present Address: Anatomy and Cell Biology, Medical Faculty, Saarland University, Homburg, Saar, Germany."}], "LastName": "Kesharwani", "ForeName": "Ajay", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Corporate R & D Centre, HLL Lifecare Limited, Akkulum, Thiruvananthapuram, Kerala, 695 017, India."}], "LastName": "Polachira", "ForeName": "Suja Kizhiyedath", "Initials": "SK"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Corporate R & D Centre, HLL Lifecare Limited, Akkulum, Thiruvananthapuram, Kerala, 695 017, India."}], "LastName": "Nair", "ForeName": "Reshmi", "Initials": "R"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Reproductive Cell Biology Laboratory, National Institute of Immunology, Aruna Asaf Ali Marg, New Delhi, 110 067, India."}], "LastName": "Agarwal", "ForeName": "Aakanksha", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Reproductive Cell Biology Laboratory, National Institute of Immunology, Aruna Asaf Ali Marg, New Delhi, 110 067, India."}], "LastName": "Mishra", "ForeName": "Nripendra Nath", "Initials": "NN"}, {"Identifier": ["0000-0003-3717-0436"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Reproductive Cell Biology Laboratory, National Institute of Immunology, Aruna Asaf Ali Marg, New Delhi, 110 067, India. skgupta@nii.ac.in."}], "LastName": "Gupta", "ForeName": "Satish Kumar", "Initials": "SK"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "England", "MedlineTA": "BMC Complement Altern Med", "NlmUniqueID": "101088661", "ISSNLinking": "1472-6882"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Antiviral Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Benzopyrans"}, {"RegistryNumber": "0", "NameOfSubstance": "Glucosides"}, {"RegistryNumber": "0", "NameOfSubstance": "Hydrolyzable Tannins"}, {"RegistryNumber": "0", "NameOfSubstance": "Plant Extracts"}, {"RegistryNumber": "18942-26-2", "NameOfSubstance": "chebulinic acid"}, {"RegistryNumber": "23094-71-5", "NameOfSubstance": "chebulagic acid"}, {"RegistryNumber": "X4HES1O11F", "NameOfSubstance": "Acyclovir"}], "MeshHeadingList": [{"QualifierName": ["pharmacology", "therapeutic use"], "DescriptorName": "Acyclovir"}, {"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["pharmacology", "therapeutic use"], "DescriptorName": "Antiviral Agents"}, {"QualifierName": ["pharmacology", "therapeutic use"], "DescriptorName": "Benzopyrans"}, {"QualifierName": [], "DescriptorName": "Chlorocebus aethiops"}, {"QualifierName": [], "DescriptorName": "Fruit"}, {"QualifierName": ["pharmacology", "therapeutic use"], "DescriptorName": "Glucosides"}, {"QualifierName": ["drug therapy", "virology"], "DescriptorName": "Herpes Simplex"}, {"QualifierName": ["drug effects"], "DescriptorName": "Herpesvirus 2, Human"}, {"QualifierName": ["pharmacology", "therapeutic use"], "DescriptorName": "Hydrolyzable Tannins"}, {"QualifierName": [], "DescriptorName": "Inhibitory Concentration 50"}, {"QualifierName": [], "DescriptorName": "Phytotherapy"}, {"QualifierName": ["pharmacology", "therapeutic use"], "DescriptorName": "Plant Extracts"}, {"QualifierName": ["chemistry"], "DescriptorName": "Terminalia"}, {"QualifierName": [], "DescriptorName": "Vero Cells"}, {"QualifierName": ["drug effects"], "DescriptorName": "Virus Attachment"}, {"QualifierName": ["drug effects"], "DescriptorName": "Virus Replication"}]}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Brugha R, Keersmaekers K, Renton A, Meheus A. Genital herpes infection: a review. Int J Epidemiol. 1997;26:698\u2013709. doi: 10.1093/ije/26.4.698.", "ArticleIdList": ["10.1093/ije/26.4.698", "9279600"]}, {"Citation": "Severson JL, Tyring SK. Relation between herpes simplex viruses and human immunodeficiency virus infections. Arch Dermatol. 1999;135:1393\u201397. doi: 10.1001/archderm.135.11.1393.", "ArticleIdList": ["10.1001/archderm.135.11.1393", "10566840"]}, {"Citation": "Looker KJ, Garnett GP, Schmid GP. An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection. Bull World Health Organ. 2008;86:805\u201312. doi: 10.2471/BLT.07.046128.", "ArticleIdList": ["10.2471/BLT.07.046128", "PMC2649511", "18949218"]}, {"Citation": "Whitley RJ, Roizman B. Herpes simplex virus infections. Lancet. 2001;357:1513\u20138. doi: 10.1016/S0140-6736(00)04638-9.", "ArticleIdList": ["10.1016/S0140-6736(00)04638-9", "11377626"]}, {"Citation": "Cassady KA, Whitley RJ. New therapeutic approaches to the alphaherpesvirus infections. J Antimicrob Chemother. 1997;39:119\u201328. doi: 10.1093/jac/39.2.119.", "ArticleIdList": ["10.1093/jac/39.2.119", "9069530"]}, {"Citation": "Englund JA, Zimmerman ME, Swierkosz EM, Goodman JL, Scholl DR, Balfour HHJ. Herpes simplex virus resistant to acyclovir. A study in a tertiary care center. Ann Intern Med. 1990;112:416\u201322. doi: 10.7326/0003-4819-76-3-112-6-416.", "ArticleIdList": ["10.7326/0003-4819-76-3-112-6-416", "2155570"]}, {"Citation": "Erlich KS, Mills J, Chatis P, Mertz GJ, Busch DF, Follansbee SE, et al. Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome. N Engl J Med. 1989;320:293\u20136. doi: 10.1056/NEJM198902023200506.", "ArticleIdList": ["10.1056/NEJM198902023200506", "2536136"]}, {"Citation": "Bean B. Antiviral therapy: current concepts and practices. Clin Microbiol Rev. 1992;5:146\u201382. doi: 10.1128/CMR.5.2.146.", "ArticleIdList": ["10.1128/CMR.5.2.146", "PMC358233", "1576586"]}, {"Citation": "De Clercq E. Current lead natural products for the chemotherapy of human immunodeficiency virus (HIV) infection. Med Res Rev. 2000;20:323\u201349. doi: 10.1002/1098-1128(200009)20:5<323::AID-MED1>3.0.CO;2-A.", "ArticleIdList": ["10.1002/1098-1128(200009)20:5<323::AID-MED1>3.0.CO;2-A", "10934347"]}, {"Citation": "Newman DJ, Cragg GM, Snader KM. Natural products as sources of new drugs over the period 1981\u20132002. J Nat Prod. 2003;66:1022\u201337. doi: 10.1021/np030096l.", "ArticleIdList": ["10.1021/np030096l", "12880330"]}, {"Citation": "Kitazato K, Wang Y, Kobayashi N. Viral infectious disease and natural products with antiviral activity. Drug Discov Ther. 2007;1:14\u201322.", "ArticleIdList": ["22504360"]}, {"Citation": "el Mekkawy S, Meselhy MR, Kusumoto IT, Kadota S, Hattori M, Namba T. Inhibitory effects of Egyptian folk medicines on human immunodeficiency virus (HIV) reverse transcriptase. Chem Pharm Bull. 1995;43:641\u20138. doi: 10.1248/cpb.43.641.", "ArticleIdList": ["10.1248/cpb.43.641", "7541317"]}, {"Citation": "Yukawa TA, Kurokawa M, Sato H, Yoshida Y, Kageyama S, Hasegawa T, et al. Prophylactic treatment of cytomegalovirus infection with traditional herbs. Antiviral Res. 1996;32:63\u201370. doi: 10.1016/0166-3542(95)00978-7.", "ArticleIdList": ["10.1016/0166-3542(95)00978-7", "8891165"]}, {"Citation": "Badmaev V, Nowakowski M. Protection of epithelial cells against influenza A virus by a plant derived biological response modifier Ledretan-96. Phytother Res. 2000;14:245\u20139. doi: 10.1002/1099-1573(200006)14:4<245::AID-PTR571>3.0.CO;2-O.", "ArticleIdList": ["10.1002/1099-1573(200006)14:4<245::AID-PTR571>3.0.CO;2-O", "10861966"]}, {"Citation": "Kurokawa M, Nagasaka K, Hirabayashi T, Uyama S, Sato H, Kageyama T, et al. Efficacy of traditional herbal medicines in combination with acyclovir against herpes simplex virus type 1 infection in vitro and in vivo. Antiviral Res. 1995;27:19\u201337. doi: 10.1016/0166-3542(94)00076-K.", "ArticleIdList": ["10.1016/0166-3542(94)00076-K", "7486956"]}, {"Citation": "Oyuntsetseg N, Khasnatinov MA, Molor-Erdene P, Oyunbileg J, Liapunov AV, Danchinova GA, et al. Evaluation of direct antiviral activity of the Deva-5 herb formulation and extracts of five Asian plants against influenza A virus H3N8. BMC Complement Altern Med. 2014;14:235. doi: 10.1186/1472-6882-14-235.", "ArticleIdList": ["10.1186/1472-6882-14-235", "PMC4227079", "25012588"]}, {"Citation": "Gupta PC. Biological and pharmacological properties of Terminalia chebula Retz. (Haritaki)- An overview. Int J Pharm Pharm Sci. 2012;4(Suupl 3):62\u20138."}, {"Citation": "Juang LJ, Sheu SJ, Lin TC. Determination of hydrolyzable tannins in the fruit of Terminalia chebula Retz. by high-performance liquid chromatography and capillary electrophoresis. J Sep Sci. 2004;27:718\u201324. doi: 10.1002/jssc.200401741.", "ArticleIdList": ["10.1002/jssc.200401741", "15387468"]}, {"Citation": "Kumar KJ. Effect of geographical variation on contents of tannic acid, gallic acid, chebulinic acid and ethyl gallate in Terminalia chebula fruits. Nat Prod. 2006;2:100\u20134."}, {"Citation": "Lin LT, Chen TY, Chung CY, Noyce RS, Grindley TB, McCormick C, et al. Hydrolyzable tannins (chebulagic acid and punicalagin) target viral glycoprotein-glycosaminoglycan interactions to inhibit herpes simplex virus 1 entry and cell-to-cell spread. J Virol. 2011;85:4386\u201398. doi: 10.1128/JVI.01492-10.", "ArticleIdList": ["10.1128/JVI.01492-10", "PMC3126266", "21307190"]}, {"Citation": "Lin LT, Chen TY, Lin SC, Chung CY, Lin TC, Wang GH, et al. Broad-spectrum antiviral activity of chebulagic acid and punicalagin against viruses that use glycosaminoglycans for entry. BMC Microbiol. 2013;13:187. doi: 10.1186/1471-2180-13-187.", "ArticleIdList": ["10.1186/1471-2180-13-187", "PMC3750913", "23924316"]}, {"Citation": "Alonso-Salces RM, Korta E, Barranco A, Berrueta LA, Gallo B, Vicente F. Determination of polyphenolic profiles of Basque cider apple varieties using accelerated solvent extraction. J Agric Food Chem. 2001;49:3761\u20137. doi: 10.1021/jf010021s.", "ArticleIdList": ["10.1021/jf010021s", "11513662"]}, {"Citation": "Benthin B, Danz H, Hamburger M. Pressurized liquid extraction of medicinal plants. J Chromatogr A. 1999;837:211\u20139. doi: 10.1016/S0021-9673(99)00071-0.", "ArticleIdList": ["10.1016/S0021-9673(99)00071-0", "10227181"]}, {"Citation": "Blaho JA, Morton ER, Yedowitz JC. Herpes simplex virus: propagation, quantification, and storage. Curr Protoc Microbiol. 2005;Chapter 14:Unit 14E.1-23.", "ArticleIdList": ["18770556"]}, {"Citation": "Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65:55\u201363. doi: 10.1016/0022-1759(83)90303-4.", "ArticleIdList": ["10.1016/0022-1759(83)90303-4", "6606682"]}, {"Citation": "Cheng HY, Lin TC, Yang CM, Wang KC, Lin LT, Lin CC. Putranjivain A from Euphorbia jolkini inhibits both virus entry and late stage replication of herpes simplex virus type 2 in vitro. J Antimicrob Chemother. 2004;53:577\u201383. doi: 10.1093/jac/dkh136.", "ArticleIdList": ["10.1093/jac/dkh136", "14998984"]}, {"Citation": "Wachsman MB, Castilla V, de Ruiz Holgado AP, de Torres RA, Sesma F, Coto CE. Enterocin CRL35 inhibits late stages of HSV-1 and HSV-2 replication in vitro. Antiviral Res. 2003;58:17\u201324. doi: 10.1016/S0166-3542(02)00099-2.", "ArticleIdList": ["10.1016/S0166-3542(02)00099-2", "12719003"]}, {"Citation": "Shigeta S, Mori S, Baba M, Ito M, Honzumi K, Nakamura K, et al. Antiviral activities of ribavirin, 5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide, and 6\u2032-(R)-6\u2032-C methylneplanocin A against several ortho- and paramyxoviruses. Antimicrob Agents Chemother. 1992;36:435\u20139. doi: 10.1128/AAC.36.2.435.", "ArticleIdList": ["10.1128/AAC.36.2.435", "PMC188453", "1605607"]}, {"Citation": "Cheng HY, Lin CC, Lin TC. Antiherpes simplex virus type 2 activity of casuarinin from the bark of Terminalia arjuna Linn. Antiviral Res. 2002;55:447\u201355. doi: 10.1016/S0166-3542(02)00077-3.", "ArticleIdList": ["10.1016/S0166-3542(02)00077-3", "12206882"]}, {"Citation": "Spear PG. Herpes simplex virus: receptors and ligands for cell entry. Cell Microbiol. 2004;6:401\u201310. doi: 10.1111/j.1462-5822.2004.00389.x.", "ArticleIdList": ["10.1111/j.1462-5822.2004.00389.x", "15056211"]}, {"Citation": "Heldwein EE, Krummenacher C. Entry of herpes viruses into mammalian cells. Cell Mol Life Sci. 2008;65:1653\u201368. doi: 10.1007/s00018-008-7570-z.", "ArticleIdList": ["10.1007/s00018-008-7570-z", "PMC11131758", "18351291"]}, {"Citation": "Elion GB. Acyclovir: discovery, mechanism of action, and selectivity. J Med Virol. 1993;Suppl 1:2\u20136. doi: 10.1002/jmv.1890410503.", "ArticleIdList": ["10.1002/jmv.1890410503", "8245887"]}, {"Citation": "Baliga MS. Triphala, Ayurvedic formulation for testing and preventing cancer: a review. J Altern Complement Med. 2010;16:1301\u20138. doi: 10.1089/acm.2009.0633.", "ArticleIdList": ["10.1089/acm.2009.0633", "21138390"]}, {"Citation": "Hazra B, Sarkar R, Biswas S, Mandal N. Comparative study of the antioxidant and reactive oxygen species scavenging properties in the extracts of the fruits of Terminalia chebula, Terminalia belerica and Emblica officinalis. BMC Complement Altern Med. 2010;10:20. doi: 10.1186/1472-6882-10-20.", "ArticleIdList": ["10.1186/1472-6882-10-20", "PMC2887379", "20462461"]}, {"Citation": "Lee HS, Jung SH, Yun BS, Lee KW. Isolation of chebulic acid from Terminalia chebula Retz. and its antioxidant effect in isolated rat hepatocytes. Arch Toxicol. 2007;81:211\u20138. doi: 10.1007/s00204-006-0139-4.", "ArticleIdList": ["10.1007/s00204-006-0139-4", "16932919"]}, {"Citation": "Suchalatha S, Shyamala Devi CS. Protective effect of Terminalia chebula against experimental myocardial injury induced by isoproterenol. Indian J Exp Biol. 2004;42:174\u20138.", "ArticleIdList": ["15282950"]}, {"Citation": "Malekzadeh F, Ehsanifar H, Shahamat N, Levin M, Colwell RR. Antibacterial activity of black myrobalan (Terminalia chebula Retz.) against Helicobactor pyroli. Int J Antimicrob Agents. 2001;18:85\u20138. doi: 10.1016/S0924-8579(01)00352-1.", "ArticleIdList": ["10.1016/S0924-8579(01)00352-1", "11463533"]}, {"Citation": "Bag A, Bhattacharyya SK, Chattopadhyay RR. The development of Terminalia chebula Retz. (Combretaceae) in clinical research. Asian Pac J Trop Biomed. 2013;3:244\u201352. doi: 10.1016/S2221-1691(13)60059-3.", "ArticleIdList": ["10.1016/S2221-1691(13)60059-3", "PMC3631759", "23620847"]}, {"Citation": "Afshari AR, Sadeghnia HR, Mollazadeh H. A review on potential mechanisms of Terminalia chebula in alzheimer\u2019s disease. Adv Pharmacol Sci. 2016. doi 10.1155/2016/8964849.", "ArticleIdList": ["PMC4749770", "26941792"]}, {"Citation": "Yang Y, Xiu J, Liu J, Zhang L, Li X, Xu Y, et al. Chebulagic acid, a hydrolyzable tannin, exhibited antiviral activity in vitro and in vivo against human enterovirus 71. Int J Mol Sci. 2013;14:9618\u201327. doi: 10.3390/ijms14059618.", "ArticleIdList": ["10.3390/ijms14059618", "PMC3676802", "23644889"]}, {"Citation": "Kim JH, Koo YC, Hong CO, Yang SY, Jun W, Lee KW. Mutagenicity and oral toxicity studies of Terminalia chebula. Phytother Res. 2012;26:39\u201347. doi: 10.1002/ptr.3504.", "ArticleIdList": ["10.1002/ptr.3504", "21538627"]}, {"Citation": "Kaur S, Grover IS, Singh M, Kaur S. Antimutagenicity of hydrolyzable tannins from Terminalia chebula in Salmonella thyphimurium. Mutat Res. 1998;419:169\u201379. doi: 10.1016/S1383-5718(98)00130-2.", "ArticleIdList": ["10.1016/S1383-5718(98)00130-2", "9804945"]}, {"Citation": "Gunness P, Aleksa K, Bend J, Koren G. Acyclovir-induced nephrotoxicity: the role of the acyclovir aldehyde metabolite. Transl Res. 2011;158:290\u2013301. doi: 10.1016/j.trsl.2011.07.002.", "ArticleIdList": ["10.1016/j.trsl.2011.07.002", "22005269"]}, {"Citation": "Rao NK, Nammi S. Antidiabetic and renoprotective effects of the chloroform extract of Terminalia chebula Retz. seeds in streptozotocin-induced diabetic rats. BMC Complement Altern Med. 2006;6:17. doi: 10.1186/1472-6882-6-17.", "ArticleIdList": ["10.1186/1472-6882-6-17", "PMC1540439", "16677399"]}]}], "History": [{"Year": "2016", "Month": "6", "Day": "24"}, {"Year": "2017", "Month": "2", "Day": "2"}, {"Year": "2017", "Month": "2", "Day": "16", "Hour": "6", "Minute": "0"}, {"Year": "2017", "Month": "2", "Day": "16", "Hour": "6", "Minute": "0"}, {"Year": "2017", "Month": "2", "Day": "24", "Hour": "6", "Minute": "0"}, {"Year": "2017", "Month": "2", "Day": "14"}], "PublicationStatus": "epublish", "ArticleIdList": ["28196487", "PMC5310005", "10.1186/s12906-017-1620-8", "10.1186/s12906-017-1620-8"]}}]}